Merrill keeps Nektar at buy

Nektar Therapeutics maintained its buy rating from Merrill Lynch analyst Hari Sambasivam. Merrill estimates for the quarter include total revenues of $34 million, including $21 million of collaborative research, total expenses of $67.5 million, and pro-forma net loss of $33 million, or $0.39 per share. Consensus loss per share for the quarter is $0.38. During the company's conference call, the analyst will be looking for updates regarding Nektar's pipeline products. Shares of the San Carlos, Calif., pharmaceutical company were down 26 cents, or 1.19%, at $21.50 on volume of 1,531,303 shares versus the three-month running average of 1,839,410 shares. (Nasdaq: NKTR)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.